Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2017

Open Access 01-12-2017 | Letter to the Editor

Mitochondrial DNA sequencing demonstrates clonality of peritoneal implants of borderline ovarian tumors

Authors: Giulia Girolimetti, Pierandrea De Iaco, Martina Procaccini, Riccardo Panzacchi, Ivana Kurelac, Laura Benedetta Amato, Giulia Dondi, Giacomo Caprara, Claudio Ceccarelli, Donatella Santini, Anna Maria Porcelli, Anna Myriam Perrone, Giuseppe Gasparre

Published in: Molecular Cancer | Issue 1/2017

Login to get access

Abstract

Borderline ovarian tumors are rare low malignant potential neoplasms characterized by the absence of stromal invasion, whose main prognostic factors are stage and type of peritoneal implants. The latter are defined as invasive when cell proliferation invades the underlying tissue (peritoneal surface, omentum and intestinal wall), or noninvasive. It is still unknown if these implants are metastatic spread from the primary ovarian mass or a neoplastic transformation de novo of the peritoneal surface. Mitochondrial DNA sequencing was performed to assess clonality in eight patients presenting both borderline ovarian tumors and implants. In 37.5% of the cases, the same mitochondrial DNA mutation was present in both borderline ovarian tumors and the peritoneal implant, being this evidence that implants may arise as a consequence of a spread from a single ovarian site.
Appendix
Available only for authorised users
Literature
1.
Lenhard MS, Mitterer S, Kumper C, Stieber P, Mayr D, Ditsch N, et al. Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort. Eur J Obstet Gynecol Reprod Biol. 2009;145:189–94.CrossRefPubMed
2.
Jones MB. Borderline ovarian tumors: current concepts for prognostic factors and clinical management. Clin Obstet Gynecol. 2006;49:517–25.CrossRefPubMed
3.
Manek S, Wells M. Pathology of borderline ovarian tumours. Clin Oncol R Coll Radiol G B. 1999;11:73–7.CrossRef
4.
Menczer J, Chetrit A, Sadetzki S. The effect of hysterectomy on survival of patients with borderline ovarian tumors. Gynecol Oncol. 2012;125:372–5.CrossRefPubMed
5.
Lalwani N, Shanbhogue AKP, Vikram R, Nagar A, Jagirdar J, Prasad SR. Current update on borderline ovarian neoplasms. AJR Am J Roentgenol. 2010;194:330–6.CrossRefPubMed
6.
Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol. 2000;31:539–57.CrossRefPubMed
7.
Silva EG, Gershenson DM, Malpica A, Deavers M. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol. 2006;30:1367–71.CrossRefPubMed
8.
Gershenson DM, Silva EG, Tortolero-Luna G, Levenback C, Morris M, Tornos C. Serous borderline tumors of the ovary with noninvasive peritoneal implants. Cancer. 1998;83:2157–63.CrossRefPubMed
9.
Abu-Rustum NR, Sonoda Y. Transperitoneal laparoscopic staging with aortic and pelvic lymph node dissection for gynecologic malignancies. Gynecol Oncol. 2007;104:5–8.CrossRefPubMed
10.
Lu KH, Bell DA, Welch WR, Berkowitz RS, Mok SC. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res. 1998;58:2328–30.PubMed
11.
Sieben NL, Roemen GMJM, Oosting J, Fleuren GJ, van Engeland M, Prat J. Clonal analysis favours a monoclonal origin for serous borderline tumours with peritoneal implants. J Pathol. 2006;210:405–11.CrossRefPubMed
12.
Guerra F, Girolimetti G, Perrone AM, Procaccini M, Kurelac I, Ceccarelli C, et al. Mitochondrial DNA genotyping efficiently reveals clonality of synchronous endometrial and ovarian cancers. Mod Pathol Off J U S Can Acad Pathol Inc. 2014;27:1412–20.
13.
Guerra F, Kurelac I, Magini P, Cormio A, Santini D, Ceccarelli C, et al. Mitochondrial DNA genotyping reveals synchronous nature of simultaneously detected endometrial and ovarian cancers. Gynecol Oncol. 2011;122:457–8.CrossRefPubMed
14.
Guerra F, Kurelac I, Cormio A, Zuntini R, Amato LB, Ceccarelli C, et al. Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma. Hum Mol Genet. 2011;20:2394–405.CrossRefPubMed
15.
Calabrese C, Simone D, Diroma MA, Santorsola M, Gutta C, Gasparre G, et al. MToolBox: a highly automated pipeline for heteroplasmy annotation and prioritization analysis of human mitochondrial variants in high-throughput sequencing. Bioinforma Oxf Engl. 2014;30:3115–7.CrossRef
16.
Santorsola M, Calabrese C, Girolimetti G, Diroma MA, Gasparre G, Attimonelli M. A multi-parametric workflow for the prioritization of mitochondrial DNA variants of clinical interest. Hum Genet. 2016;135:121–36.CrossRefPubMed
17.
Rubino F, Piredda R, Calabrese FM, Simone D, Lang M, Calabrese C, et al. HmtDB, a genomic resource for mitochondrion-based human variability studies. Nucleic Acids Res. 2012;40:D1150–1159.CrossRefPubMed
18.
Kurelac I, Lang M, Zuntini R, Calabrese C, Simone D, Vicario S, et al. Searching for a needle in the haystack: comparing six methods to evaluate heteroplasmy in difficult sequence context. Biotechnol Adv. 2012;30:363–71.CrossRefPubMed
19.
Mazurek S, Shoshan MC. Tumor Cell Metabolism Pathways, Regulation and Biology. Wien: u.a.: Springer; 2015.
20.
Larman TC, DePalma SR, Hadjipanayis AG, Protopopov A, Zhang J, Gabriel SB, et al. Spectrum of somatic mitochondrial mutations in five cancers. Proc Natl Acad Sci U S A. 2012;109:14087–91.CrossRefPubMedPubMedCentral
21.
Park JS, Sharma LK, Li H, Xiang R, Holstein D, Wu J, et al. A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. Hum Mol Genet. 2009;18:1578–89.CrossRefPubMedPubMedCentral
22.
Masuda S, Kadowaki T, Kumaki N, Tang X, Tokuda Y, Yoshimura S, et al. Analysis of gene alterations of mitochondrial DNA D-loop regions to determine breast cancer clonality. Br J Cancer. 2012;107:2016–23.CrossRefPubMedPubMedCentral
23.
Geurts-Giele WRR, Gathier GHGK, Atmodimedjo PN, Dubbink HJ, Dinjens WNM. Mitochondrial D310 mutation as clonal marker for solid tumors. Virchows Arch Int J Pathol. 2015;467:595–602.CrossRef
24.
Aikhionbare FO, Mehrabi S, Kumaresan K, Zavareh M, Olatinwo M, Odunsi K, et al. Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages. J Carcinog. 2007;6:1.CrossRefPubMedPubMedCentral
Metadata
Title
Mitochondrial DNA sequencing demonstrates clonality of peritoneal implants of borderline ovarian tumors
Authors
Giulia Girolimetti
Pierandrea De Iaco
Martina Procaccini
Riccardo Panzacchi
Ivana Kurelac
Laura Benedetta Amato
Giulia Dondi
Giacomo Caprara
Claudio Ceccarelli
Donatella Santini
Anna Maria Porcelli
Anna Myriam Perrone
Giuseppe Gasparre
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2017
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-017-0614-y

Other articles of this Issue 1/2017

Molecular Cancer 1/2017 Go to the issue

Research

Role of the lncRNA ABHD11-AS1 in the tumorigenesis and progression of epithelial ovarian cancer through targeted regulation of RhoC

Review

Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells

Research

miR-19a promotes colorectal cancer proliferation and migration by targeting TIA1

Research

The depletion of PinX1 involved in the tumorigenesis of non-small cell lung cancer promotes cell proliferation via p15/cyclin D1 pathway

Research

MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway

Research

Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits